Combined Therapy of AXL and HDAC Inhibition Reverses Mesenchymal Transition in Diffuse Intrinsic Pontine Glioma.
Michaël H MeelMark Cornelis de GooijerDennis S MetselaarA Charlotte P SewingKenn ZwaanPiotr WaraneckiMarjolein BreurLevi C M BuilTonny LagerweijLaurine E WedekindJos W R TwiskJan KosterRintaro HashizumeEric H RaabeÁngel Montero CarcabosoMarianna BugianiTimothy N PhoenixOlaf van TellingenDannis G van VuurdenGertjan J L KaspersEsther HullemanPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Combined inhibition of AXL and HDACs in DIPG cells results in a synergistic antitumor effect by reversing their mesenchymal, stem cell-like, therapy-resistant phenotype. As such, this treatment combination may serve as part of a future multimodal therapeutic strategy for DIPG.